Best Pulmonology Journals 2026: Respiratory Journal Fit Guide

If your paper needs a broad clinical consequence, submit first to The Lancet Respiratory Medicine, AJRCCM, or ERJ. If your study needs a practical pulmonary or sleep-medicine audience, choose CHEST or Respiratory Medicine. If your main value is lung mechanism, choose AJRCMB or Respiratory Research before forcing the manuscript into a clinical flagship.

Choose The Lancet Respiratory Medicine only when the manuscript has respiratory importance plus a wider clinical or public-health reason to care. Large randomized trials, global-burden analyses, practice-changing diagnostic evidence, and major respiratory infection or chronic-lung-disease studies can fit. A strong single-center cohort or careful mechanistic study usually does not have enough general reach.

The practical test is whether a non-respiratory clinical reader can understand the consequence from the abstract alone. If the paper needs a long COPD, ILD, asthma, or pulmonary vascular background section before the importance is visible, AJRCCM, ERJ, CHEST, Thorax, or a disease-specific journal may be more realistic.

American Journal of Respiratory and Critical Care Medicine is the ATS flagship and one of the default top targets for serious pulmonary, critical-care, and sleep-medicine work. It can handle clinical trials, translational respiratory science, ATS guideline-adjacent work, ICU-related respiratory research, and disease-specific studies when the pulmonary consequence is broad enough.

AJRCCM is often stronger than The Lancet Respiratory Medicine when the paper is clearly respiratory-specialist work rather than general clinical medicine. It is also a better fit than basic-science journals when the mechanism is tied to patient-facing respiratory disease, treatment response, or clinical phenotype.

European Respiratory Journal is the ERS flagship and competes directly with AJRCCM for high-level respiratory submissions. It is especially strong when the work speaks to European respiratory practice, ERS guideline context, multicenter registries, respiratory epidemiology, or translational evidence that respiratory specialists can act on.

For many authors, the AJRCCM-versus-ERJ decision is not about which JIF is larger. It is about audience. If your collaborators, comparators, guideline references, and target conference are ERS-centered, ERJ may be cleaner. If the paper is ATS-centered or has a stronger North American clinical practice context, AJRCCM may be cleaner.

CHEST is strongest when the paper is clinically practical for pulmonary, critical-care, sleep, or interventional pulmonology readers. A bronchoscopy, pulmonary embolism, sleep-apnea, ICU respiratory management, or clinical-practice question may fit CHEST better than a more citation-heavy but less clinically focused venue.

Thorax is strongest for respiratory clinical research, epidemiology, health-services work, and population-facing pulmonary evidence. A well-designed respiratory cohort, environmental exposure study, or public-health respiratory paper can be more credible at Thorax than at a flagship that expects a wider clinical consequence.

Respiratory Research, ERJ Open Research, BMJ Open Respiratory Research, and BMC Pulmonary Medicine are legitimate open-access routes when the paper is methodologically sound and the reader pool fits. They are not interchangeable.

Respiratory Research is useful for broad clinical, translational, and basic respiratory studies. ERJ Open Research keeps the paper in the ERS ecosystem. BMJ Open Respiratory Research is strongest for clinical and epidemiologic work that benefits from BMJ-style open-access visibility. BMC Pulmonary Medicine can work for accessible clinical respiratory research, especially when the manuscript is solid but not built for a flagship screen.

Sending critical-care papers to journals that do not read them as critical care. Mechanical ventilation, ARDS, ICU respiratory support, sepsis-associated respiratory failure, and acute care pathways need a journal whose reviewers routinely read ICU methods and endpoints. AJRCCM and CHEST can work; a pulmonology-only title may not.

Treating asthma, COPD, ILD, and pulmonary hypertension as one audience. These fields share respiratory medicine, but the reviewer expectations differ. Asthma papers with immunology may belong near allergy and clinical immunology readers. Pulmonary hypertension papers may need vascular specialists. ILD cohorts need imaging, diagnosis, and phenotype clarity that generic respiratory journals will not infer.

Choosing by JIF before choosing by endpoint. A respiratory paper with a modest but well-measured patient endpoint can outperform at CHEST, Thorax, AnnalsATS, or Respiratory Medicine because the reviewer pool understands the question. A higher-JIF title does not repair a narrow, underpowered, or misframed endpoint.

Submitting lung biology as if it were clinical pulmonology. Airway epithelial biology, fibroblast activation, alveolar macrophage work, organoid data, and animal lung-injury models need clinical framing if they target AJRCCM or ERJ. If the durable contribution is mechanism, AJRCMB or Respiratory Research may give the paper better reviewers.

Overclaiming post-pandemic respiratory relevance. COVID, long COVID, and respiratory-infection context can help a paper, but only when the methods actually support a respiratory outcome. A broad infection or fatigue paper with a small pulmonary-function subgroup may not be a pulmonology paper.

In our review work on respiratory and clinical-medicine manuscripts, the weak journal choice is usually visible before the full methods section: the abstract names the wrong audience, the first table does not support the claimed clinical consequence, or the disease-specific story is being pushed into a broader respiratory journal without enough generalizable value.

Clinical-consequence claims without a practice-level endpoint. We see respiratory cohorts aimed at The Lancet Respiratory Medicine, AJRCCM, or ERJ because the disease area is serious and the dataset is large. Editors still ask whether the endpoint changes diagnosis, prognosis, treatment, guideline interpretation, or public-health action. If the primary result is descriptive or exploratory, CHEST, Thorax, AnnalsATS, Respiratory Medicine, or a disease-specific journal may be the stronger first target.

Check whether your respiratory endpoint supports the target journal ->

Mechanistic lung biology framed as clinical respiratory medicine. A paper can be biologically strong and still miss AJRCCM or ERJ if the patient relevance is asserted rather than demonstrated. For airway epithelial models, immune-cell mechanisms, animal injury models, or omics-first lung biology, the key audit is whether the clinical phenotype, validation set, or translational bridge is visible in the first screen.

Check whether your lung-biology story has enough clinical bridge ->

Respiratory infection or long-COVID framing without pulmonary specificity. We often see manuscripts use respiratory language because the disease started in the lung, while the durable contribution is actually infectious disease, neurology, cardiology, rehabilitation, or general medicine. If pulmonary function, imaging, symptoms, respiratory physiology, or respiratory treatment is not central, a pulmonology journal may be the wrong reviewer pool.

Check whether your post-viral or infection paper belongs in respiratory medicine ->

This guide tells you what respiratory journals look for by venue type; the review tells you whether YOUR paper passes the audience, endpoint, methods, figure, limitation, and cover-letter checks for that target. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Overrated: raw JIF ordering. The JIF table makes The Lancet Respiratory Medicine, ERJ, and AJRCCM look like a simple ladder. In real submission strategy, the ladder splits. The Lancet Respiratory Medicine needs wider clinical consequence; AJRCCM and ERJ need respiratory-specialist strength; CHEST and Thorax can be better for practical clinical or epidemiologic work.

Underrated: society ecosystem fit. ATS and ERS journals are not just names in a ranking table. They connect to conferences, guidelines, reviewer pools, and specialist communities. A paper that is clearly built for ATS or ERS readers can do better by staying inside that ecosystem than by chasing a less relevant high-JIF title.

Underrated: the clinical-versus-mechanistic boundary. Respiratory medicine includes both patient-facing care and lung biology. The best target is often decided by which contribution would still matter if the JIF number disappeared: clinical decision, public-health signal, disease mechanism, method, or open-access visibility.

For a solid clinical respiratory paper that does not need a flagship screen, Respiratory Medicine, BMC Pulmonary Medicine, BMJ Open Respiratory Research, or ERJ Open Research may be the practical route. The right choice depends on APC budget, institutional open-access coverage, and whether the paper benefits from ERS, BMJ, BMC, or Elsevier readership.

Do not use speed alone as the deciding variable. Respiratory papers often depend on reporting details that slow review if missing: pulmonary-function methods, imaging definitions, endpoint hierarchy, comorbidity handling, subgroup plans, and data availability. Fixing those before submission is usually faster than changing journals after avoidable reviewer objections.

Before submitting a pulmonology manuscript, verify the target journal's current author instructions, article type, open-access route, data-sharing requirements, reporting guideline expectations, and scope. Then ask the journal-fit question in manuscript terms: does the title, abstract, first figure, methods, and cover letter make the respiratory audience obvious?

Do this before upload, not after rejection. If the target asks for a structured abstract of 250 words, match it. If your funder requires open access, do not assume a $3,000 APC budget is enough; verify the accepted-date price and institutional agreement status on the publisher page. If the journal wants trial registration, data-sharing language, imaging definitions, or pulmonary-function reporting, make those items visible before the editor has to look for them.

A respiratory journal-fit check can pressure-test the specific manuscript against target-journal fit, endpoint support, reporting completeness, and claim strength before upload.

Last verified: July 7, 2026 against the local 2025 JIF master from the 2026 JCR release, SCImago pulmonary and respiratory medicine category context, ATS journals, ERS journals, The Lancet Respiratory Medicine, and Manusights respiratory submission-fit review patterns. Check JCR directly for exact rank tables because annual updates shift rankings.

This page was created from Clarivate JCR-release context, SCImago pulmonary/respiratory category context, official society-journal positioning, and Manusights pre-submission review work on respiratory and clinical-medicine submission fit. In that work, the recurring mistake is choosing by citation tier before deciding whether the manuscript is clinical pulmonology, critical care, respiratory epidemiology, lung biology, pulmonary vascular disease, sleep medicine, or open-access clinical respiratory research.